Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma
Last Updated: Friday, October 6, 2023
This review article highlights the proven efficacy of CD19-directed CAR T-cell therapy among patients with relapsed/refractory DLBCL, as well the myriad barriers preventing some eligible patients from receiving this novel treatment—including cost of therapy, patient hesitancy, and timely patient selection—and recommendations to overcome these barriers.
Advertisement
News & Literature Highlights
